CNSP 0.14 CNS Pharmaceuticals, Inc.
| Range: | 0.096-137.5 | Vol Avg: | 4552714 | Last Div: | 0 | Changes: | 0 |
| Beta: | 1.05 | Cap: | 0.00B | Currency: | USD | Exchange: | NASDAQ |
| Sector: | Healthcare | IPO: | Fri Nov 08 2019 | Empoloyees: | 3 | ||
| CUSIP: | 18978H102 | CIK: | 0001729427 | ISIN: | US18978H2013 | Country: | US |
| CEO: | Mr. John Michael Climaco Esq., J.D. | Website: | https://www.cnspharma.com | ||||
CNS Pharmaceuticals, Inc., a clinical pharmaceutical company, engages in the development of anti-cancer drug candidates for the treatment of brain and central nervous system tumors. The company's lead drug candidate is Berubicin, an anthracycline that is in Phase I and II clinical trials that is used for the treatment of glioblastoma multiforme. It has license agreements with Houston Pharmaceuticals, Inc. and The University of Texas M.D. Anderson Cancer Center, as well as Animal Life Sciences, LLC; and a development agreement with WPD Pharmaceuticals Inc., as well as a collaboration agreement with Reata Pharmaceuticals, Inc. The company was incorporated in 2017 and is based in Houston, Texas.
Stock Details
CNSP 0.5
Maxim Group Upgrades CNS Pharmasceuticals Inc. (CNSP) to Buy, 'Berubicin Glioblastoma Data is Coming into View'
Jason McCarthy·Tue Sep 10 2024
Maxim Group
About The Monevue
The content provided on this site is for informational purposes only and does not constitute financial, investment, or professional advice. We are not registered investment advisors or financial planners, and we do not provide recommendations or advice on buying, selling, or holding any particular stocks or securities. Any investment decisions should be made based on your own research and consultation with a qualified financial professional. We are not responsible for any financial loss or damages incurred from reliance on the information provided on this site. Please invest responsibly and seek professional advice when needed.
• Powered by StackThrow